Detalles de la búsqueda
1.
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
J Med Econ
; 20(4): 328-336, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27841717
2.
Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
J Med Econ
; 19(10): 936-44, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27149298
3.
Medical resource use and costs associated with chylomicronemia.
J Med Econ
; 16(5): 657-66, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23428107
4.
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Pediatr Pulmonol
; 48(10): 954-61, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23255309
5.
Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives.
Circ Cardiovasc Qual Outcomes
; 6(1): 18-26, 2013 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23212458
6.
Cost utility of hub-and-spoke telestroke networks from societal perspective.
Am J Manag Care
; 19(12): 976-85, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24512034
7.
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Clin Drug Investig
; 31(9): 665-74, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21819162
Resultados
1 -
7
de 7
1
Próxima >
>>